The Stockholm Stock Exchange fell for the second day in a row on Wednesday. The trend is weaker than what is seen on the major European stock exchanges. The market is gearing up for tomorrow, which will bring several central bank announcements, including from the Riksbank and the ECB, as well as US inflation figures. The ongoing peace efforts in the Ukraine war are also in focus.

At 12:20 p.m., the OMXS30 index was down 0.34 percent to 2,803.36. Shares worth approximately SEK 4.5 billion were traded on the Stockholm Stock Exchange.

Energy was the best performer among the stock market's major industrial sectors, with an increase of 1.3 percent. At the other end of the scale, technology was at the bottom with a decline of 1.3 percent.

Among the leading stocks included in the OMXS30 index, Boliden rose 2.4 percent, while Saab B was up 1.4 percent. Nibe B performed the worst, down 2.2 percent, while Assa Abloy B was down 2.0 percent.

Medical technology company Vitrolife fell 4 percent after announcing a restructuring program within the Genetic Services product group and that the company is taking a goodwill write-down of SEK 5.4 billion related to the acquisition of Igenomix. The measures mean that 6 percent of the workforce will be laid off and that restructuring costs of SEK 55 million will be reported in the fourth quarter. The program is expected to generate annual savings of approximately SEK 65 million, with full effect at the end of the third quarter of 2026.

Mattias Danielsson, CEO of cybersecurity company Yubico, is stepping down from his role. At the same time, he will contribute to an orderly handover to the company's COO Jerrod Chong, who will take over as acting CEO. The share price is down 1.5 percent.

Biotechnology company Hansa Biopharma announces that the phase 3 study with imlifidase for the treatment of anti-glomerular basement membrane disease did not achieve its primary efficacy endpoint. The outcome is a setback for the company's development program in this indication. The share price falls 18 percent.

Icelandic biotech company Alvotech provides guidance for next year as the company launches a $100 million bond offering. The company is targeting revenue of $650 to $700 million and adjusted EBITDA of $180 to $220 million, supported by higher volumes and new product launches. The share price fell 1.3 percent.

Investment bank JP Morgan has placed industrial company SKF on negative catalyst watch ahead of its fourth-quarter report on January 30. At the same time, it has reiterated its neutral recommendation. The target price has been lowered to SEK 245 from SEK 250. The share price fell 1.4 percent.

Installation company Bravida Denmark has been awarded a framework agreement with an estimated total value of DKK 300 million, equivalent to approximately SEK 438 million. At the same time, Danske Bank is initiating coverage of Bravida with a buy recommendation. The share rose 0.9 percent.

Animal health company Swedencare presents new financial targets for the next five years. Among other things, the targets mean that the company will achieve double-digit organic growth each year. The share price rises 2.5 percent.

Road maintenance company Terranor was down nearly 11 percent. The company's major German shareholder, Mutares Holding-39, has sold 2.5 million shares, corresponding to 12.5 percent of the capital, in the company. The sale was made to a limited number of Swedish and international institutional investors and other qualified investors.

On the analysis front, it is also noted that SEB has raised the industrial company AQ to buy from hold. The share rose 2.3 percent.

SEB and SB1 Markets are initiating coverage of game developer Coffee Stain with a buy recommendation, while Nordea is initiating coverage with a hold recommendation. The share is up 2.6 percent.

Nordea resumes coverage of gaming company Embracer with a buy recommendation. The share rises 1.8 percent.

Handelsbanken has downgraded technology consulting company Rejlers to hold from buy. The share price fell 8.1 percent.

New Street raises telecom operator Tele2 to a buy from neutral. The share rises 1.2 percent.

Pareto resumes coverage with a buy recommendation on hygiene and health company Essity. The B share rises 0.4 percent.